Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/24073
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bermel, R. | - |
dc.contributor.author | Comi, G. | - |
dc.contributor.author | Eralinna, J. -P. | - |
dc.contributor.author | Leist, T. P. | - |
dc.contributor.author | Nicholas, R. | - |
dc.contributor.author | Oreja-Guevara, C. | - |
dc.contributor.author | Siva, A. | - |
dc.contributor.author | VAN WIJMEERSCH, Bart | - |
dc.contributor.author | Wiendl, H. | - |
dc.contributor.author | Bernasconi, C. | - |
dc.contributor.author | Buffels, R. | - |
dc.contributor.author | Csoboth, C. | - |
dc.contributor.author | Han, J. | - |
dc.contributor.author | Musch, B. | - |
dc.contributor.author | Vermersch, P. | - |
dc.date.accessioned | 2017-08-04T12:24:40Z | - |
dc.date.available | 2017-08-04T12:24:40Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | MULTIPLE SCLEROSIS JOURNAL, 22, p. 615-616 (Art N° P1180) | - |
dc.identifier.issn | 1352-4585 | - |
dc.identifier.uri | http://hdl.handle.net/1942/24073 | - |
dc.description.sponsorship | Sponsored by F. Hoffmann-La Roche Ltd. | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS LTD | - |
dc.title | Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatment | - |
dc.type | Journal Contribution | - |
local.bibliographicCitation.conferencedate | SEP 14-17, 2016 | - |
local.bibliographicCitation.conferencename | 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) | - |
local.bibliographicCitation.conferenceplace | London, ENGLAND | - |
dc.identifier.epage | 616 | - |
dc.identifier.spage | 615 | - |
dc.identifier.volume | 22 | - |
local.format.pages | 2 | - |
local.bibliographicCitation.jcat | M | - |
dc.description.notes | [Bermel, R.] Cleveland Clin, Mellen Ctr MS, Cleveland, OH 44106 USA. [Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy. [Eralinna, J. -P.] NEO Res, Turku, Finland. [Leist, T. P.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Nicholas, R.] Imperial Coll Healthcare NHS Trust, London, England. [Nicholas, R.] Imperial Coll, London, England. [Oreja-Guevara, C.] Hosp Clin San Carlos, Madrid, Spain. [Siva, A.] Istanbul Univ, Cerrahpasa Sch Med, Cerrahpasa, Turkey. [Van Wijmeersch, B.] Univ Hasselt, Hasselt, Belgium. [Van Wijmeersch, B.] Rehabil & MS Ctr Overpelt, Hasselt, Belgium. [Wiendl, H.] Univ Munster, Munster, Germany. [Bernasconi, C.; Buffels, R.] F Hoffmann La Roche Ltd, Basel, Switzerland. [Csoboth, C.; Han, J.; Musch, B.] Genentech Inc, San Francisco, CA 94080 USA. [Vermersch, P.] Ctr Hosp Reg Univ Lille, Lille, France. | - |
local.publisher.place | LONDON | - |
local.type.refereed | Refereed | - |
local.type.specified | Meeting Abstract | - |
local.bibliographicCitation.artnr | P1180 | - |
dc.identifier.isi | 000383267202379 | - |
dc.identifier.url | https://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/145863/robert.bermel.design.of.two.phase.iii.open-label.trials.evaluating.ocrelizumab.html?f=p6m3e1031o14005 | - |
item.fulltext | With Fulltext | - |
item.contributor | Bermel, R. | - |
item.contributor | Comi, G. | - |
item.contributor | Eralinna, J. -P. | - |
item.contributor | Leist, T. P. | - |
item.contributor | Nicholas, R. | - |
item.contributor | Oreja-Guevara, C. | - |
item.contributor | Siva, A. | - |
item.contributor | VAN WIJMEERSCH, Bart | - |
item.contributor | Wiendl, H. | - |
item.contributor | Bernasconi, C. | - |
item.contributor | Buffels, R. | - |
item.contributor | Csoboth, C. | - |
item.contributor | Han, J. | - |
item.contributor | Musch, B. | - |
item.contributor | Vermersch, P. | - |
item.fullcitation | Bermel, R.; Comi, G.; Eralinna, J. -P.; Leist, T. P.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Bernasconi, C.; Buffels, R.; Csoboth, C.; Han, J.; Musch, B. & Vermersch, P. (2016) Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatment. In: MULTIPLE SCLEROSIS JOURNAL, 22, p. 615-616 (Art N° P1180). | - |
item.accessRights | Open Access | - |
crisitem.journal.issn | 1352-4585 | - |
crisitem.journal.eissn | 1477-0970 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Abstract.pdf | Peer-reviewed author version | 261.39 kB | Adobe PDF | View/Open |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.